A Study to Compare PK, PD and Safety of the AD-213-A and AD-2131
NCT04690868
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
43
Enrollment
INDUSTRY
Sponsor class
Conditions
Gastroesophagus Reflux Disease
Interventions
DRUG:
AD-213-A
DRUG:
AD-2131
Sponsor
Addpharma Inc.